Medgenics Announces Results of 2014 Annual Meeting of Stockholders

WAYNE, Pa. and MISGAV, Israel, April 9, 2014 (GLOBE NEWSWIRE) — Medgenics, Inc.(NYSE:MDGN) (AIM:MEDU) (AIM:MEDG), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that all resolutions proposed at the Company’s Annual Meeting of Stockholders held yesterday were duly passed.

This entry was posted in Recent Development News: Q2 - 2014. Bookmark the permalink.